Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.

Bixia Tang,Zhihong Chi,Yingbo Chen,Xiufeng Liu,Di Wu,Jing Chen,Xin Song,Weifeng Wang,Lihou Dong,Haifeng Song,Hai Wu,Hui Feng,Sheng Yao,Shuikui Qin,Xiaoshi Zhang, Jun Guo

user-5f8cf9244c775ec6fa691c99（2020）

引用 82|浏览8

暂无评分

摘要

In the earlier version of [this article][1] as it was published online on July 21, 2020 ([1][2]) and in the printed article, the Results section contained incorrect progression-free survival values at 3.6 months. The values in the abstract were correct (95% confidence interval, 2.7–5.3). The HTML

查看译文

关键词

Confidence interval,MEDLINE,Biomarker Analysis,Oncology,Polaris,Medicine,Advanced melanoma,Internal medicine,Previously treated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要